Comparative Pharmacology
Head-to-head clinical analysis: INGREZZA versus VALBENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INGREZZA versus VALBENAZINE.
INGREZZA vs VALBENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vesicular monoamine transporter 2 (VMAT2) inhibitor; reduces presynaptic dopamine release.
Vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing dopamine release in the striatum.
80 mg orally once daily; may titrate from 40 mg once daily for 7 days to reduce nausea.
50 mg orally once daily; can be increased to 75 mg orally once daily based on tolerability and response.
None Documented
None Documented
Terminal elimination half-life of deutetrabenazine is 9-10 hours; clinical context: supports twice-daily dosing.
Terminal elimination half-life is approximately 17-23 hours, allowing for once-daily dosing.
Clinical Note
moderateValbenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Cyclosporine
Approximately 60% renal (as unchanged drug and metabolites) and 30% fecal.
Primarily hepatic metabolism; less than 30% of the dose excreted unchanged in urine and feces combined. Biliary/fecal excretion accounts for approximately 40-60% as metabolites.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Valbenazine."